☆
4.7
Letter
PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Export Citation
No citation available
Rate this paper
The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More